Search Results
May 30, 2026, 09:07 ET Menarini Group apresenta novos dados do estudo ELEVATE de Fase 1b/2 sobre o elacestranto em associação com o capivasertibe em pacientes com câncer de mama metastático (CMm) ER+, HER2- no Congresso Anual de 2026 da American Society of Clinical Oncology (ASCO)
elacestranto (258-345 mg) mais capivasertibe (320-400 mg) (n=31), que demonstram um benefício preliminar na sobrevida média livre de progressão (mPFS) na coorte da dose recomendada para a fase 2 (RP2D). A RP2D foi determinada na coorte 2 (n=9) como sendo 345 mg de elacestranto mais 320 mg de capivasertibe
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:02 ET Menarini Group presenta nuevos datos del ensayo ELEVATE de fase 1b/2 de elacestrant combinado con capivasertib en pacientes con cáncer de mama metastásico (CMM) con receptores de estrógeno positivos (ER+) y HER2 negativo (HER2-) en la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) de 2026
elacestrant (258-345 mg) más capivasertib (320-400 mg) (n=31), que demuestran la mediana preliminar del beneficio de supervivencia libre de progresión (mPFS) en la cohorte de dosis recomendada de fase 2 (RP2D). Se determinó que la RP2D en la cohorte 2 (n=9) era 345 mg de elacestrant más 320 mg de capivasertib
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 06:52 ET Menarini Group、ASCO2026でER+/HER2-転移性乳がん対象エラセストラント・カピバセルチブ併用ELEVATE試験の新データを発表
の治療レジメンで構成されています。ASCO2026で報告されるELEVATE試験の結果（抄録番号1098）[1]には、第1b相エラセストラント（258～345mg）＋カピバセルチブ（320～400mg）コホート（n=31）の安全性および予備的有効性データが含まれ、推奨第2相用量（RP2D）コホートにおける無増悪生存期間中央値（mPFS）の予備的ベネフィットが示されています。RP2Dはコホート2（n=9）で、エラセストラント345mg＋カピバセルチブ320mgを1日2回（4日間投与/3日間休薬）と決定されました。RP2Dの奏効評価可能な患者では、
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 17:06 ET Die Menarini Group präsentiert auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) neue Daten aus der Phase-1b/2-Studie ELEVATE zu Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER-positivem, HER2-negativem metastasiertem Brustkrebs (mBC)
Elacestrant (258–345 mg) plus Capivasertib (320–400 mg) (n = 31), die einen vorläufigen Vorteil hinsichtlich des medianen progressionsfreien Überlebens (mPFS) in der Kohorte mit der empfohlenen Phase-2-Dosis (RP2D) belegen. In Kohorte 2 (n = 9) wurde die empfohlene Tagesdosis (RP2D) auf 345 mg Elacestrant plus
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 11:40 ET Le Groupe Menarini présente de nouvelles données de l'étude ELEVATE sur l'association de l'élacestrant et du capivasertib
(résumé 1098)[1] comprennent les données d'innocuité et d'efficacité préliminaire des cohortes de phase 1b élacestrant (258-345 mg) plus capivasertib (320-400 mg) (n=31), qui démontrent un bénéfice préliminaire sur le plan de la survie médiane sans progression (mPFS) dans la cohorte à la dose recommandée
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 10:53 ET Fox ESS anuncia su cambio de marca antes de la feria SNEC, presentando una nueva trayectoria de marca
Video - https://mma.prnewswire.com/media/2989568/final_MG_video.mp4Logo - https://mma.prnewswire.com/media/2989536/5991642/Fox_ESS_logo.jpg
More news about: Fox ESS
May 29, 2026, 10:50 ET Fox ESS kondigt zijn rebranding aan in aanloop naar de SNEC-beurs en luidt daarmee een nieuw hoofdstuk voor het merk in.
Video - https://mma.prnewswire.com/media/2989568/final_MG_video.mp4Logo - https://mma.prnewswire.com/media/2989536/5991642/Fox_ESS_logo.jpg
More news about: Fox ESS
May 29, 2026, 10:46 ET Fox ESS annonce son repositionnement de marque avant l'exposition SNEC, dévoilant un nouveau parcours de marque
Vidéo - https://mma.prnewswire.com/media/2989568/final_MG_video.mp4 Logo - https://mma.prnewswire.com/media/2989536/5991642/Fox_ESS_logo.jpg
More news about: Fox ESS
May 29, 2026, 10:13 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 ER+, HER2- 전이성 유방암(mBC) 환자를 대상으로 엘라세스트란트와 카피바서팁 병용요법을 평가한 1b/2상 ELEVATE 시험 신규 데이터 발표
있다.ASCO 2026에서 보고되는 ELEVATE 결과(초록 1098)[1]에는 제1b상 엘라세스트란트(258~345mg)와 카피바서팁(320~400mg) 병용 코호트(n=31)의 안전성 및 예비 유효성 데이터가 포함되며, 권장 2상 용량(RP2D) 코호트에서 예비 중위 무진행 생존기간(mPFS) 이익을 입증했다. RP2D는 코호트 2(n=9)에서 엘라세스트란트 345mg과 카피바서팁 320mg 1일 2회(BID)(4일 투여/3일 휴약)로 결정됐다.RP2D 반응 평가 가능 환자에서 예비 유효성은 질병 조절률(DCR)
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 10:00 ET Myasthenia Gravis Foundation of America (MGFA) Announces the Start of Myasthenia Gravis Awareness Month Around the World
years to diagnose MG, which is too long to live with life-changing symptoms. Raising awareness about MG can potentially help those impacted find treatments quicker - taking action for broader MG awareness can make a difference.In light of the damaging impact of the disease, MG community members
More news about: Myasthenia Gravis Foundation of America, Inc.
May 29, 2026, 09:33 ET Novo Nordisk amplia acesso à semaglutida biológica com preços até 50% mais baixos para tratamento de obesidade e diabetes no Brasil
para Wegovy® na dosagem 2,4 mg permite a aquisição de 3 (três) canetas pelo preço de 2 (duas). As condições especiais para Wegovy® 2,4mg são válidas até o final do mês de junho.Já para Rybelsus®, seguem as condições diferenciadas em todas as dosagens de 3 mg, 7 mg e 14 mg, por tempo indeterminado.
More news about: Novo Nordisk
May 29, 2026, 09:20 ET Neues Branding, neue Ära: Fox ESS positioniert sich vor der SNEC neu
Video - https://mma.prnewswire.com/media/2989568/final_MG_video.mp4Logo - https://mma.prnewswire.com/media/2989536/Fox_ESS_logo.jpg
More news about: Fox ESS
May 29, 2026, 09:08 ET Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions
study enrolled 200 overweight and obese adults without diabetes to evaluate the efficacy and safety of Efsubaglutide α at doses ranging from 5 to 20 mg for 18 weeks. Results showed that all dose groups experienced significant weight loss from baseline, superior to the placebo group, and the weight loss
More news about: Innogen Pharmaceuticals
May 29, 2026, 08:52 ET Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
As of January 16, 2026, 324 patients were randomized in a 1:1 ratio to receive either ZEGFROVY or chemotherapy. ZEGFROVY, administered at 300 mg once daily, demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS), the primary endpoint of
More news about: Dizal Pharmaceutical
May 29, 2026, 08:18 ET New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, ie, 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing
More news about: Johnson & Johnson
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
first dose of VENCLYXTO and at each dose increase. During post marketing surveillance, TLS, including fatal events, has been reported after a single 20 mg dose of venetoclax. The risk of TLS is a continuum based on multiple factors, including comorbidities (particularly reduced renal function), tumour burden,
More news about: AbbVie
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
first dose of VENCLYXTO and at each dose increase. During post marketing surveillance, TLS, including fatal events, has been reported after a single 20 mg dose of venetoclax. The risk of TLS is a continuum based on multiple factors, including comorbidities (particularly reduced renal function), tumour burden,
More news about: AbbVie
May 29, 2026, 05:23 ET Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib
(258-345 mg) más capivasertib (320-400 mg) (n=31), que demuestran un beneficio preliminar en la mediana de supervivencia libre de progresión (mPFS) en la cohorte de dosis recomendada para la fase 2 (RP2D). La RP2D se determinó en la cohorte 2 (n=9) como elacestrant 345 mg más capivasertib 320 mg dos veces
More news about: Menarini Industrie Farmaceutiche Riunite
May 28, 2026, 19:26 ET Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
(mOS) was 14.7 months in US patients, where the median follow up time is 14.7 months. The efficacy data for 3 mg/kg spevatamig + GnP is still maturing. 3 mg/kg has the potential to be the dose level for a Phase 3 registrational study. Overall, the data support further
More news about: Phanes Therapeutics, Inc.
May 28, 2026, 19:10 ET FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
1-800-FDA-1088.Dosage Forms and Strengths: TREMFYA® is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.ABOUT JOHNSON & JOHNSONAt Johnson & Johnson,
More news about: Johnson & Johnson
May 28, 2026, 13:15 ET Braeburn Presents New Data at 2026 ASCP Annual Meeting Demonstrating Opioid Withdrawal Suppression at Low Buprenorphine Plasma Concentrations
found:Utilization of all available doses of BRIXADI Weekly (8 mg: 15.7%, 16 mg: 18.6%, 24 mg: 36.1%, 32 mg: 29.6% of 61,087 units dispensed) and Monthly (64 mg: 20.5%, 96 mg: 35.2%, 128 mg: 44.4% of 173,082 units dispensed).Some patients (29.6%) changed
More news about: Braeburn
May 28, 2026, 13:00 ET Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.Learn moreZepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979)
More news about: Eli Lilly and Company
May 28, 2026, 13:00 ET Bucked Up® Brings the Carnival to the Snack Aisle With Two New Launches
with zero sugar, zero artificial colors, and the full performance formula behind every Bucked Up® Energy on the shelf. Each 16 fl oz can delivers 300mg of natural caffeine and a performance stack that includes TeaCrine, Dynamine, AlphaSize, Beta-Alanine, and Huperzine A. This is a single production run
More news about: Bucked Up
May 28, 2026, 13:00 ET McCune Law Group Investigates True Metrix Blood Glucose Monitor Recall
Pro devices display an "E-5" error code in two distinct situations: when a user is experiencing a dangerously high blood glucose event exceeding 600 mg/dL, and when a test strip has simply malfunctioned. The device's original instruction booklet did not tell patients which situation they were facing, leaving
More news about: McCune Law Group APC
May 28, 2026, 12:46 ET Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
elacestrant (258-345 mg) plus capivasertib (320-400 mg) cohorts (n=31), which demonstrate preliminary median progression-free survival (mPFS) benefit in the recommended phase 2 dose (RP2D) cohort. The RP2D was determined in cohort 2 (n=9) to be elacestrant 345 mg plus capivasertib 320 mg BID (4 days on/3
More news about: Menarini Industrie Farmaceutiche Riunite